Table 4.
Population parameter estimates of the final time‐to‐event models
| Parameter | Covariate | Unit | Estimate (RSE, %) | Bootstrap mean | Bootstrap median | Bootstrap 90% CI |
|---|---|---|---|---|---|---|
| Patients with mRCC | ||||||
| λ0 | Weeks‐1 | 0.0118 (46.3) | 0.0121 | 0.0117 | 0.0038–0.0220 | |
| ß | sVEGFR‐2 baseline valuea | ‐ | 1.45 (43.3) | 1.57 | 1.49 | 0.71–2.68 |
| HR | ‐ | 4.26 | 4.81 | 4.44 | 2.03–14.59 | |
| Patients with mCRC | ||||||
| λ0 | Weeks‐1 | 0.0234 | 0.0256 | 0.0241 | 0.0120–0.0447 | |
| ß | ACu | mL/ng | −0.758 | −0.919 | −0.836 | −0.366 to −1.736 |
| HR | ‐ | 0.47 | 0.40 | 0.43 | 0.18–0.69 | |
ACU, unbound active concentration (sunitinib + SU12662); ß, regression coefficient; CI, confidence interval; HR, hazard ratio; λ0, baseline hazard; mCRC, metastasized colorectal cancer; mRCC, metastasized renal cell carcinoma; RSE, relative standard error; sVEGFR, soluble vascular endothelial growth factor receptor.
a
Dichotomized above (1) and below (0) population median.